Skip to main content

Table 2 Nonalcoholic fatty liver disease (NAFLD) activity score in the five groups

From: Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

  Steatosis Lobular inflammation Ballooning NAS
Control 0 0 0 0
Vehicle 1.3 ± 0.5 2.3 ± 0.5 2 5.7 ± 0.8
Linagliptin 10 mg/Kg 0.8 ± 0.4 2.2 ± 0.4 2 5.0 ± 0.6
Empagliflozin 10 mg/Kg 1 1.3 ± 0.5 1.0 ± 0.6 3.3 ± 0.5
Linagliptin + empagliflozin 0.8 ± 0.4 2 1 3.8 ± 0.4
  1. Data are mean ± SD
  2. NAS nonalcoholic fatty liver disease (NAFLD) activity score